(PharmaNewsWire.Com, October 10, 2019 ) Market Overview: The Pediatric Clinical Trails Market was valued at USD xx million in 2018 and is forecasted to reach USD xx million by 2026, with a CAGR of xx% during the forecast period (2019-2026).
Market Dynamics: According to FDA stats, nearly 60% of the drugs used for children were not approved for pediatric use. This situation is increasing the demand for the pediatric clinical trials. “Rising chronical pediatric diseases upsurge the demand for pediatric clinical trials.”
However, new regulatory policies of the FDA and EMEA for approved and investigational drugs for children are raising the need for the medications with customized dosages as per the age groups. As per the stats of U.S. FDA, as of February 2017, a total of 935 pediatric study requests were received. All of these scenarios are driving the market for Pediatric Clinical Trails.
Also, the outburst of infectious diseases like Dengue, Cholera, etc., is increasing the demand for the pediatric clinical trials market across the globe.
Market Segmentation: Paediatric Clinical Trails Market -By Phases: • Phase I • Phase II • Phase III • Phase IV
About Us: DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year we have secured more than 100 unique customers from established organizations all over the world.
For more information: Sai Kiran Sales Manager at Data M Intelligence Email: pr@datamintelligence.com Tel: +1 877 441 4866 Website: www.datamintelligence.com
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
